Pramlintide is a synthetic analogue of human amylin; in a 52-week trial in 651 people with type 1 diabetes, mealtime pramlintide added to insulin lowered HbA1c by 0.29-0.34% more than placebo, with a small weight loss and transient nausea.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Pramlintide is a synthetic analogue of human amylin; in a 52-week trial in 651 people with type 1 diabetes, mealtime pramlintide added to insulin lowered HbA1c by 0.29-0.34% more than placebo, with a small weight loss and transient nausea. · pmid:15498087
In 656 insulin-treated people with type 2 diabetes, pramlintide 120 micrograms twice daily lowered HbA1c by about 0.6% over a year, with weight loss against weight gain on placebo. · pmid:12610038
Proportion of the 2 claims about Pramlintide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Pramlintide yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. · pmid 12610038 · 2003
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. · pmid 15498087 · 2004
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.